Gateway, which assists pharma firms in the early phase production of molecules for research and development, was bought by Chemir in May, as it sought to expand its range of pharmaceutical contract manufacturing services.
US-based Chemir Group already had a number of contract businesses under its umbrella - Chemir Analytical Services, Azopharma, a pharmaceutical contract service provider located in Florida, and CAS-MI, a laboratory serving the paints, coatings, and polymer industries - however, Gateway offered the firm the chance to branch out into a new specialty.
"As our Chemir group of companies serves more and more pharmaceutical clients, we recognise the need for a broad and diverse offering of contract service providers," said Shri Thanedar, CEO of Chemir Analytical Services.
"Clients had been requesting synthetic chemistry services, and we sought an acquisition to best fill this need," said Thanedar.
Specific synthesis services brought by newly-named IQsynthesis include molecules of pharmaceutical intermediates, bioorganic compounds, as well as specialty, fine and agrochemicals, from milligram to multi-kilogram scales.
"These molecules are the first steps in the development of new medications and therapies," said Robert Kaufman, president of IQsynthesis.
"We help large and small companies save time, stay on schedule, and attain their goal of creating molecules."
Other services include synthesis of analytical standards, metabolites, toxicology lot batches, stable isotope labelled compounds, key intermediates, custom surfactants, combinational platforms, extraction/purification of natural products and process development.
Chemir said it now plans to expand the laboratory space and number of staff at IQsynthesis, as well as develop new infrastructure and systems for cGMP-regulated synthesis.